Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL	Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral arterial disease, cerebral infarction, cerebrovascular disorder, dementia, hereditary disease, intracranial arterial disease, ischemic disease, nervous system disorder, stroke disorder, vascular dementia, vascular disorder	Not yet recruiting	Phase 2	2026-07-09		NCT07692399

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Huashan Hospital	165
Jiangsu Simcere Pharmaceutical Co., Ltd.	24

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Huashan Hospital, Fudan University	Shanghai	China	18